Through the partnership, the two parties aim to accelerate the global advancement of ISM8969—an orally available, brain penetrant NLRP3 inhibitor for Central Nervous System (CNS) disorders.
BGE-102 has the potential for therapeutic retinal exposure with oral delivery, reducing treatment burden in ocular indications currently treated with intravitreal therapies ... .
BGE-102 has the potential for therapeutic retinal exposure with oral delivery, reducing treatment burden in ocular indications currently treated with intravitreal therapies ... .
BioAge announces indication expansion for oral NLRP3 inhibitor BGE-102, with plans to initiate Phase 1b/2a proof-of-concept clinical trial in patients with diabetic macular edema in mid-2026.
One of these options involves the use of substances called environmental inhibitors (EIs) that can help mitigate methane emissions from cows and other livestock, and limit the loss of nitrogen from fertilizers used on farms.
) BackHKU Chemists Develop First-in-Class InhibitorTargeting a Key Epigenetic Regulator ... Using structure-guided design, the researchers developed a potent and highly selective inhibitor of YEATS2, named LS-170.
The company also provided an update on the continued clinical advancement of BT-267, its highly selective, brain-optimized leucine rich repeat kinase 2 (LRRK2) inhibitor ... Brain-Selective NLRP3Inhibitor Advancing to First-in-Human Evaluation.
Tumors with this defect are vulnerable to PARP inhibitors, which further disrupt DNA repair, causing cancer cells to accumulate DNA damage and die ... if patients will benefit from PARP inhibitors.
Together, these findings support CS014 as a differentiated and potentially safer HDAC inhibitor with broad therapeutic potential in thrombotic and fibrosis-driven diseases ... our HDAC inhibitor platform.